• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Alkermes plc (Amendment)

    2/13/24 4:59:03 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALKS alert in real time by email
    SC 13G/A 1 tv0227-alkermesplc.htm SCHEDULE 13G/A alkermesplc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 13)*

    Name of issuer:  Alkermes PLC

    Title of Class of Securities:  Common Stock

    CUSIP Number:  G01767105

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  G01767105

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    304,392

    7.  SOLE DISPOSITIVE POWER

    20,476,822

    8.  SHARED DISPOSITIVE POWER

    478,632

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    20,955,454

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    12.56%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Alkermes PLC

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    Connaught House, 1 Burlington Road
    Dublin 4

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    G01767105

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $ALKS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALKS

    DatePrice TargetRatingAnalyst
    7/15/2025$43.00Buy
    Goldman
    6/17/2025$42.00Neutral → Buy
    UBS
    5/28/2025$45.00Buy
    Needham
    3/13/2025$40.00Sector Perform
    RBC Capital Mkts
    3/4/2025$21.00 → $38.00Sell → Neutral
    UBS
    2/11/2025$40.00Buy
    Deutsche Bank
    11/5/2024$25.00 → $36.00Hold → Buy
    Stifel
    6/17/2024$34.00Buy
    TD Cowen
    More analyst ratings

    $ALKS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alkermes plc Reports Second Quarter 2025 Financial Results

    —    Second Quarter Revenues of $390.7 Million — —    GAAP Net Income of $87.1 Million and Diluted GAAP Earnings per Share of $0.52 — —    Company Reiterates 2025 Financial Expectations — —    Alkermes to Present Detailed Vibrance-1 Results at Upcoming World Sleep Congress — DUBLIN, July 29, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the second quarter of 2025. "Our second quarter results reflect strong performance across all three of our proprietary products and robust profitability and cash flow generation," said Richard Pops, Chief Executive Officer of Alkermes. "Against the backdrop of solid financial performance, the recently announced positive

    7/29/25 7:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1

    – Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1 – – Alixorexton Demonstrated Robust and Consistent Improvements in Patient-Reported Outcomes Related to Disease Severity, Fatigue and Cognition at All Doses Tested – – Alixorexton Was Generally Well Tolerated at All Doses Tested – – Detailed Results to Be Presented at Upcoming World Sleep Congress – – Data Support Advancement of Alixorexton to Phase 3 Development in Narcolepsy – DUBLIN, July 21, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced positive topline results from the randomized double-bli

    7/21/25 6:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes to Report Second Quarter Financial Results on July 29, 2025

    DUBLIN, July 15, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 29, 2025 to discuss the company's second quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website.  About Alkermes plcAlkermes plc is a global biopharmaceutical

    7/15/25 4:00:00 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Alkermes Plc with a new price target

    Goldman initiated coverage of Alkermes Plc with a rating of Buy and set a new price target of $43.00

    7/15/25 8:39:38 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes Plc upgraded by UBS with a new price target

    UBS upgraded Alkermes Plc from Neutral to Buy and set a new price target of $42.00

    6/17/25 7:46:56 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham initiated coverage on Alkermes Plc with a new price target

    Needham initiated coverage of Alkermes Plc with a rating of Buy and set a new price target of $45.00

    5/28/25 8:55:31 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CLO, Alkermes, Inc. Gaffin David Joseph converted options into 2,014 units of Ordinary Shares and covered exercise/tax liability with 895 units of Ordinary Shares, increasing direct ownership by 0.55% to 205,374 units (SEC Form 4)

    4 - Alkermes plc. (0001520262) (Issuer)

    8/4/25 4:43:11 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Chief Commercial Officer Nichols Christian Todd sold $210,143 worth of Ordinary Shares (6,667 units at $31.52), decreasing direct ownership by 7% to 86,208 units (SEC Form 4)

    4 - Alkermes plc. (0001520262) (Issuer)

    6/10/25 4:39:56 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Wright Christopher I converted options into 3,301 units of Ordinary Shares and covered exercise/tax liability with 793 units of Ordinary Shares, increasing direct ownership by 12% to 23,013 units (SEC Form 4)

    4 - Alkermes plc. (0001520262) (Issuer)

    6/10/25 4:37:23 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Financials

    Live finance-specific insights

    View All

    Alkermes plc Reports Second Quarter 2025 Financial Results

    —    Second Quarter Revenues of $390.7 Million — —    GAAP Net Income of $87.1 Million and Diluted GAAP Earnings per Share of $0.52 — —    Company Reiterates 2025 Financial Expectations — —    Alkermes to Present Detailed Vibrance-1 Results at Upcoming World Sleep Congress — DUBLIN, July 29, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the second quarter of 2025. "Our second quarter results reflect strong performance across all three of our proprietary products and robust profitability and cash flow generation," said Richard Pops, Chief Executive Officer of Alkermes. "Against the backdrop of solid financial performance, the recently announced positive

    7/29/25 7:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes to Report Second Quarter Financial Results on July 29, 2025

    DUBLIN, July 15, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, July 29, 2025 to discuss the company's second quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website.  About Alkermes plcAlkermes plc is a global biopharmaceutical

    7/15/25 4:00:00 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes plc Reports First Quarter 2025 Financial Results

    —    First Quarter Revenues of $306.5 Million — —    GAAP Net Income of $22.5 Million and Diluted GAAP Earnings per Share of $0.13 — —    Company Reiterates 2025 Financial Expectations — DUBLIN, May 1, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the first quarter of 2025. "Our first quarter financial performance provides a solid foundation to deliver on our financial guidance for the year. We are in a strong position in this dynamic macroeconomic environment and remain focused on executing on the strategic objectives that we believe will drive the future value of the company," said Richard Pops, Chief Executive Officer of Alkermes. "We recently achiev

    5/1/25 7:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Leadership Updates

    Live Leadership Updates

    View All

    Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

    DUBLIN, March 7, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors (the Board). Ms. Lurker is a seasoned healthcare executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong commercial expertise, including a track record of successful U.S. and global pharmaceutical product launches. "Nancy brings to the Board deep biopharmaceutical industry experience spanning executive leadership, govern

    3/7/24 7:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 1, 2023 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 18, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t

    12/1/23 6:16:00 PM ET
    $ALK
    $ALKS
    $AWI
    Air Freight/Delivery Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc

    —  Dr. Loew to Assume New Leadership Role Upon Completion of the Planned Separation of Alkermes' Oncology Business — —  Planned Separation Remains on Track to be Completed in Second Half of 2023 — DUBLIN, June 1, 2023 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced that Caroline J. Loew, Ph.D., has been appointed as the chief executive officer designate of Mural Oncology plc (Mural Oncology), the new independent public company to be established upon the planned separation of Alkermes' oncology business. Dr. Loew will join Alkermes in June as a strategic advisor and transition to CEO of Mural Oncology upon completion of the separation.  "Dr. Loew's deep knowledge of the oncology fi

    6/1/23 4:01:00 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Alkermes plc

    SC 13G - Alkermes plc. (0001520262) (Subject)

    11/14/24 1:22:34 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alkermes plc

    SC 13G/A - Alkermes plc. (0001520262) (Subject)

    11/12/24 1:28:21 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alkermes plc

    SC 13G/A - Alkermes plc. (0001520262) (Subject)

    11/8/24 10:46:38 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Alkermes plc

    SCHEDULE 13G/A - Alkermes plc. (0001520262) (Subject)

    8/14/25 1:07:20 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Alkermes plc

    S-8 - Alkermes plc. (0001520262) (Filer)

    7/29/25 4:09:29 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Alkermes plc

    10-Q - Alkermes plc. (0001520262) (Filer)

    7/29/25 9:16:10 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care